UCP3 (Uncoupling Protein 3) Insufficiency Exacerbates Left Ventricular Diastolic Dysfunction During Angiotensin II-Induced Hypertension.
Xu ChenSadia AshrafNadia AshrafRomain HarmanceyPublished in: Journal of the American Heart Association (2021)
Background Left ventricular diastolic dysfunction, an early stage in the pathogenesis of heart failure with preserved ejection fraction, is exacerbated by joint exposure to hypertension and obesity; however, the molecular mechanisms involved remain uncertain. The mitochondrial UCP3 (uncoupling protein 3) is downregulated in the heart with obesity. Here, we used a rat model of UCP3 haploinsufficiency (ucp3+/-) to test the hypothesis that decreased UCP3 promotes left ventricular diastolic dysfunction during hypertension. Methods and Results Ucp3+/- rats and ucp3+/+ littermates fed a high-salt diet (HS; 2% NaCl) and treated with angiotensin II (190 ng/kg per min for 28 days) experienced a similar rise in blood pressure (158±4 versus 155±7 mm Hg). However, UCP3 insufficiency worsened diastolic dysfunction according to echocardiographic assessment of left ventricular filling pressures (E/e'; 18.8±1.0 versus 14.9±0.6; P<0.05) and the isovolumic relaxation time (24.7±0.6 versus 21.3±0.5 ms; P<0.05), as well as invasive monitoring of the diastolic time constant (Tau; 15.5±0.8 versus 12.7±0.2 ms; P<0.05). Exercise tolerance on a treadmill also decreased for HS/angiotensin II-treated ucp3+/- rats. Histological and molecular analyses further revealed that UCP3 insufficiency accelerated left ventricular concentric remodeling, detrimental interstitial matrix remodeling, and fetal gene reprogramming during hypertension. Moreover, UCP3 insufficiency increased oxidative stress and led to greater impairment of protein kinase G signaling. Conclusions Our findings identified UCP3 insufficiency as a cause for increased incidence of left ventricular diastolic dysfunction during hypertension. The results add further support to the use of antioxidants targeting mitochondrial reactive oxygen species as an adjuvant therapy for preventing heart failure with preserved ejection fraction in individuals with obesity.
Keyphrases
- left ventricular
- blood pressure
- angiotensin ii
- oxidative stress
- hypertrophic cardiomyopathy
- heart failure
- cardiac resynchronization therapy
- acute myocardial infarction
- early stage
- aortic stenosis
- left atrial
- mitral valve
- angiotensin converting enzyme
- vascular smooth muscle cells
- hypertensive patients
- diabetic rats
- weight loss
- metabolic syndrome
- insulin resistance
- ejection fraction
- weight gain
- type diabetes
- squamous cell carcinoma
- ms ms
- physical activity
- reactive oxygen species
- heart rate
- mass spectrometry
- nitric oxide
- coronary artery disease
- risk factors
- transcription factor
- percutaneous coronary intervention
- acute coronary syndrome
- gene expression
- signaling pathway
- heat shock
- catheter ablation
- induced apoptosis
- cancer therapy